Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMEL1 | Q495T6 | 4/20 | 0.36 |
| ▸ | MME | P08473 | 3/20 | 0.36 |
| ▸ | CPB2 | Q96IY4 | 6/20 | 0.34 |
| ▸ | CPB1 | P15086 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 2/20 | 0.31 |
| ▸ | ACE | P12821 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8254490 | 1.00 | MMEL1 (0.36) | MMEL1MMECPB2CPB1SMN1; SMN2 | |
| SCHEMBL5869295 | 1.00 | MMEL1 (0.36) | MMEL1MMECPB2CPB1SMN1; SMN2 | |
| SCHEMBL16750036 | 0.90 | SMN1; SMN2 (0.35) | CPB2CPB1SMN1; SMN2 | |
| SCHEMBL5833197 | 0.90 | SMN1; SMN2 (0.35) | CPB2CPB1SMN1; SMN2 | |
| SCHEMBL5832985 | 0.90 | SMN1; SMN2 (0.35) | CPB2CPB1SMN1; SMN2 | |
| SCHEMBL20834533 | 0.88 | CPB2 (0.39) | MMEL1MMECPB2CPB1ACE | |
| SCHEMBL3138900 | 0.87 | CPB2 (0.33) | MMECPB2CPB1SMN1; SMN2LTA4H | |
| SCHEMBL16290057 | 0.87 | CPB2 (0.33) | CPB2CPB1SMN1; SMN2 | |
| SCHEMBL5870160 | 0.86 | ACE2 (0.41) | MMELTA4HACE | |
| SCHEMBL8248643 | 0.86 | ACE2 (0.41) | MMELTA4HACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | ACE, ACE2, AGTR2 | MMEL1 539/4885MME 11/4885CPB2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.